arrow
D

Daniele Marinelli

azienda ospedaliera - universita di padova
H指数:21
被引数:1,375

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Artificial intelligence-based assessment of tumor bed stroma in non-small cell lung cancer after neoadjuvant therapy: Association with pathologic response and survival. A multicenter study

基于人工智能对非小细胞肺癌新辅助治疗后肿瘤床间质的评估:与病理反应和生存期的关联。一项多中心研究

2026-09-010
PRE
Evolutionary characterization of lung cancer metastasis

肺癌转移的进化表征

Nature
IF48.5
2026-04-290
OAAI
Longitudinal ultrasensitive ctDNA monitoring for high-resolution lung cancer risk prediction

纵向超敏ctDNA监测用于高分辨率肺癌风险预测

Cell
IF42.5
2025-11-070
OAAI
Prognostic and predictive implications of tumor suppressor gene alterations in non-small cell lung cancer

肿瘤抑制基因改变在非小细胞肺癌中的预后和预测意义

2025-10-060
OA
Attrition with adjuvant, neoadjuvant, and perioperative immunotherapy-based treatment protocols in patients with resectable non-small-cell lung cancer. A meta-analysis of prospective trials

在可切除非小细胞肺癌患者中使用佐剂、新辅助和围手术期免疫治疗为基础的治疗方案的损耗情况。前瞻性试验的荟萃分析

2025-09-220
PREAI
TP53 co-mutations increase risk of recurrence in EGFR-mutated stage I lung adenocarcinoma

TP53共突变增加了EGFR突变的Ⅰ期肺腺癌的复发风险。

2025-07-100
PRE
Neoadjuvant vs perioperative chemo-immunotherapy according to pathological response in resectable non-small cell lung cancer: a reconstructed individual patient data meta-analysis

新辅助与围手术期化免疫疗法根据病理反应在可切除非小细胞肺癌中的比较:一项重构的个体患者数据meta分析

2025-06-011
PRE
Lung adenocarcinomas with mucinous histology: clinical, genomic, and immune microenvironment characterization and outcomes to immunotherapy-based treatments and KRASG12C inhibitors

黏液性组织学特征的肺腺癌:临床、基因组学和免疫微环境特征及对基于免疫疗法治疗和KRASG12C抑制剂的疗效

2025-03-014
PRE
Characterizing the evolutionary dynamics of cancer proliferation in single-cell clones with SPRINTER
2024-11-291
OAAI
Weekly carboplatin plus paclitaxel chemotherapy in advanced melanoma patients resistant to anti-PD-1 inhibitors: a retrospective, monocentric experience
2024-10-011
OAAI
Tissue- and liquid-biopsy based NGS profiling in advanced non-small-cell lung cancer in a real-world setting: the IMMINENT study
2024-07-094
OAAI
Transcriptional Phenocopies of Deleterious KEAP1 Mutations Correlate with Survival Outcomes in Lung Cancer Treated with Immunotherapy
2024-07-090
PRE
Pembrolizumab-based first-line treatment for PD-L1-positive, recurrent or metastatic head and neck squamous cell carcinoma: a retrospective analysis (vol 24, 430, 2024)

基于Pembrolizumab的一线治疗PD-L1-positive,复发或转移性头颈部鳞状细胞癌: 回顾性分析 (第24卷,430,2024)

2024-04-170
OAAI
Pembrolizumab-based first-line treatment for PD-L1-positive, recurrent or metastatic head and neck squamous cell carcinoma: a retrospective analysis

基于派姆单抗一线治疗PD-L1-positive、复发或转移性头颈部鳞状细胞癌的回顾性分析

2024-04-081
OAAI
Linking proliferation rate to the evolution of single-cell primary and metastatic tumor clones
2024-02-010
PRE
Surgical and survival outcomes with perioperative or neoadjuvant immune-checkpoint inhibitors combined with platinum-based chemotherapy in resectable NSCLC: A systematic review and meta-analysis of randomised clinical trials
2023-12-0121
OAAI